Edition:
India

Intrexon Corp (XON.N)

XON.N on New York Stock Exchange

17.94USD
20 Apr 2018
Change (% chg)

$-0.14 (-0.77%)
Prev Close
$18.08
Open
$18.11
Day's High
$18.27
Day's Low
$17.89
Volume
1,188,661
Avg. Vol
404,133
52-wk High
$26.96
52-wk Low
$10.26

Latest Key Developments (Source: Significant Developments)

Actobio Therapeutics Greenlighted By FDA To Commence A Phase Ib/Iia Trial With AG019
Thursday, 29 Mar 2018 

March 29 (Reuters) - Intrexon Corp ::ACTOBIO THERAPEUTICS GREENLIGHTED BY FDA TO COMMENCE A PHASE IB/IIA TRIAL WITH AG019 FOR THE TREATMENT OF EARLY ONSET TYPE 1 DIABETES.ACTOBIO THERAPEUTICS SAYS "SOON WILL START CLINICAL TRIALS" WITH AG019 "IN ASSOCIATION WITH SPECIALIZED INSTITUTES IN EUROPE AND NORTH AMERICA".  Full Article

Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007
Tuesday, 30 Jan 2018 

Jan 30 (Reuters) - Fibrocell Science Inc ::FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB).FIBROCELL SCIENCE INC - FCX-007, CO'S GENE THERAPY CANDIDATE, IS BEING DEVELOPED IN COLLABORATION WITH INTREXON CORPORATION.  Full Article

Intrexon Prices Public Offering Of Common Stock
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Intrexon Corp ::INTREXON PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 6 MILLION SHARES PRICED AT $12.50PER SHARE.  Full Article

Intrexon Announces Proposed Public Offering Of Common Stock
Wednesday, 17 Jan 2018 

Jan 16 (Reuters) - Intrexon Corp ::INTREXON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Intrexon posts Q3 qtrly ‍net loss per share $0.33​
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Intrexon Corp :Intrexon announces third quarter 2017 financial results.Q3 revenue $46 million versus I/B/E/S view $55.1 million.Intrexon corp - qtrly ‍net loss per share $0.33​.Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.  Full Article

Agilis Biotherapeutics announces orphan product designation approval in Europe for the treatment of friedreich ataxia
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Agilis Biotherapeutics :Agilis Biotherapeutics announces orphan product designation approval in Europe for the treatment of friedreich ataxia.‍agilis Biotherapeutics says EC granted orphan medicinal product designation in EU to company's gene therapy product candidate, AGIL-FA​.‍agilis Biotherapeutics says company has completed a pre-IND meeting with FDA and is on track to open an IND in 2018​.  Full Article

Intrexon and Arch Pharmalabs collaborate on fermentative production of an API to replace existing process sourced from animals
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Arch Pharmalabs Ltd :Intrexon and Arch Pharmalabs collaborate on fermentative production of an API to replace existing process sourced from animals.Intrexon Corp - ‍Arch Pharmalabs will have exclusive access to co's technologies for fermentation-based production of specific API.Intrexon - Will receive technology access fee, milestone payments, as well as a 40% royalty based on gross profit of commercialized products.  Full Article

Intrexon enters into $100 mln preferred stock equity facility
Tuesday, 17 Oct 2017 

Oct 16 (Reuters) - Intrexon Corp :Intrexon Corporation enters into $100 million preferred stock equity facility.Intrexon Corp - ‍under facility, Intrexon may, at its discretion, sell to investor up to $100 million of newly issued series a redeemable preferred stock​.  Full Article

Intrexon Corp says initial studies validates efficacy of dsRNA for insect control applications using its proprietary ActoBiotics platform
Tuesday, 13 Dec 2016 

Intrexon Corp :Intrexon Corp - initial studies have validated efficacy of dsRNA for insect control applications using its proprietary ActoBiotics platform.  Full Article

Intrexon to Develop Disease-Modifying Therapies in New Collaborations with Harvest Intrexon Enterprise Fund
Friday, 23 Sep 2016 

Intrexon Corp : Entered into exclusive channel collaborations with Genten Therapeutics, CRS Bio, cos backed by Harvest Intrexon Enterprise Fund . Under terms of ECC agreements for both collaborations, co will receive technology access fee in form of equity equating to 25% of each startup .Under collaborations companies will pursue new approaches to deliver disease-modifying therapies.  Full Article

BRIEF-Intrexon Corp Q4 Loss Per Share $‍0.23​

* INTREXON ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS